S. Gourgou-Bourgade

发表

Predictive factors of positive circumferential resection margin after radiochemotherapy for rectal cancer: the French randomised trial ACCORD12/0405 PRODIGE 2.

T. Conroy, A. Leroux, I. Soubeyran, 2013, European journal of cancer.

Two‐part statistics with paired data

C. Bascoul-Mollevi, S. Gourgou-Bourgade, A. Kramar, 2005, Statistics in medicine.

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Pierre Michel, Olivier Bouché, Jaafar Bennouna, 2011, The New England journal of medicine.

Clinical complete response (cCR) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer. Findings from the ACCORD 12/PRODIGE 2 randomized trial.

V. Boige, S. Gourgou-Bourgade, J. Gérard, 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Results in the elderly with locally advanced rectal cancer from the ACCOR12/PRODIGE 2 phase III trial: tolerance and efficacy.

T. Conroy, S. Gourgou-Bourgade, M. Jarlier, 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer.

T. Conroy, Y. Bécouarn, O. Bouché, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial.

T. Conroy, M. Ychou, M. Ducreux, 2010 .

Survival end point reporting in randomized cancer clinical trials: a review of major journals.

S. Mathoulin-Pélissier, F. Bonnetain, S. Gourgou-Bourgade, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer

T. Conroy, Y. Bécouarn, O. Bouché, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.

Christophe Hennequin, Bernard Denis, Pierre-Luc Etienne, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ACCORD12/0405-Prodige 2 Phase III Trial Neoadjuvant Treatment in Rectal Cancer: Results after 3 Years of Follow-up

T. Conroy, P. Romestaing, S. Gourgou-Bourgade, 2011 .

A phase III randomized trial of LV5FU2+CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802)

M. Ychou, J. Douillard, Y. Bécouarn, 2005 .

EORTC QLQ-C30 Descriptive Analysis with the qlqc30 Command

C. Bascoul-Mollevi, S. Gourgou-Bourgade, D. Azria, 2015 .

Phase III randomized French multicentric study to evaluate the impact of a localized 16-Gy boost after conservative surgery and a 50-Gy whole-breast irradiation in breast ductal carcinoma in situ (the BONBIS trial).

P. Maingon, D. Cowen, C. Bourgier, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gemcitabine and cisplatin after radical cystectomy for bladder cancer in an adjuvant setting: feasibility study from the Genito-Urinary Group of the French Federation of Cancer Centers

S. Culine, C. Théodore, S. Gourgou-Bourgade, 2006, Anti-cancer drugs.

Influence of age on chemoradiotherapy outcome in patients with rectal cancer: Exploratory analysis from the phase III study ACCORD 12/0405 PRODIGE 2.

T. Conroy, S. Gourgou-Bourgade, C. Hennequin, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III randomized trial of definitive chemoradiotherapy (CRT) with FOLFOX or cisplatin and fluorouracil in esophageal cancer (EC): Final results of the PRODIGE 5/ACCORD 17 trial.

J. Douillard, V. Boige, O. Bouché, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Selenium and the Course of Mild Graves' Orbitopathy

M. Ducreux, S. Gourgou-Bourgade, I. Sperduti, 2011 .

Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.

T. Conroy, M. Ychou, C. Bascoul-Mollevi, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oestrogen receptor negative breast cancers exhibit high cytokine content

D. Laune, F. Bibeau, S. Gourgou-Bourgade, 2007, Breast Cancer Research.

A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802).

T. Conroy, M. Ychou, M. Ducreux, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II Trial of Dose Dense Docetaxel Followed by FEC100 as Neoadjuvant Chemotherapy in Patients With Operable Breast Cancer

P. Colombo, G. Romieu, F. Bibeau, 2010, American journal of clinical oncology.

A prospective clinical and biological database for pancreatic adenocarcinoma: the BACAP cohort

S. Truant, M. Ychou, P. Colombo, 2018, BMC Cancer.

An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma

M. Buyse, T. Conroy, M. Ychou, 2016, Oncotarget.

Adapted physical activity and diet (APAD) during adjuvant breast cancer therapy: design and implementation of a prospective randomized controlled trial.

G. Romieu, G. Ninot, F. Cousson-Gélie, 2013, Contemporary clinical trials.

Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarray

M. Ychou, F. Penault-Llorca, P. Rochaix, 2006, Virchows Archiv.

Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.

T. Conroy, J. Douillard, V. Boige, 2014, The Lancet. Oncology.

Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.

S. Sleijfer, F. Collin, M. van Glabbeke, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.

S Michiels, B Asselain, J Bogaerts, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized multicenter phase III trial comparing two neoadjuvant chemoradiotherapy (CT-RT) regimens (RT45-Cap versus RT50-Capox) in patients (pts) with locally advanced rectal cancer (LARC): Results of the ACCORD 12/0405 PRODIGE 2.

T. Conroy, S. Gourgou-Bourgade, C. Hennequin, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Applying the Longitudinal Model from Item Response Theory to Assess Health-Related Quality of Life in the PRODIGE 4/ACCORD 11 Randomized Trial

C. Lavergne, T. Conroy, C. Bascoul-Mollevi, 2016, Medical decision making : an international journal of the Society for Medical Decision Making.

Comparison of three longitudinal analysis models for the health-related quality of life in oncology: a simulation study

C. Bascoul-Mollevi, F. Bonnetain, S. Gourgou-Bourgade, 2014, Health and Quality of Life Outcomes.

Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials).

Karin Haustermans, Simone Mathoulin-Pélissier, Julien Taieb, 2014, European journal of cancer.

Electrons for intraoperative radiotherapy in selected breast-cancer patients: late results of the Montpellier phase II trial

Norbert Ailleres, Philippe Rouanet, David Azria, 2013, Radiation oncology.

ACCORD12/0405-Prodige 2 phase III trial neoadjuvant treatment in rectal cancer: Results after 5 years of follow-up.

T. Conroy, O. Bouché, S. Gourgou-Bourgade, 2016 .

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials).

H. Wildiers, J. Bogaerts, J. Yarnold, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

A prospective clinical and biological database for pancreatic adenocarcinoma: the BACAP cohort

S. Truant, E. Assenat, G. Piessen, 2018, BMC Cancer.

A phase III randomised trial of LV 5 FU 2 1 irinotecan versus LV 5 FU 2 alone in adjuvant high-risk colon cancer ( FNCLCC Accord 02 / FFCD 9802 )

T. Conroy, M. Ychou, M. Ducreux, 2009 .

GERICO-03 phase II trial of accelerated and partial breast irradiation in elderly women: feasibility, reproducibility, and impact on functional status.

H. Marsiglia, E. Brain, S. Gourgou-Bourgade, 2013, Brachytherapy.

Impact on autonomy of biweekly docetaxel as first-line chemotherapy (CT) regimen in elderly patients with metastatic breast cancer (MBC) – A FNCLCC Gerico Group Phase II multicentre trial

E. Blot, V. Girre, S. Delaloge, 2008 .

T. Conroy, S. Gourgou-Bourgade, C. Hennequin, 2009, Journal of Clinical Oncology.

Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.

T. Conroy, M. Ychou, C. Bascoul-Mollevi, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival end point reporting in randomized cancer clinical trials: a review of major journals.

S. Mathoulin-Pélissier, F. Bonnetain, S. Gourgou-Bourgade, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.